ReviewMediators of inflammation2026
Targeting IL-17 Presents a Promising Strategy for Treating Diseases Related to the Dysregulation of Lipid Homeostasis.
Review in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting IL-17 Presents a Promising Strategy for Treating Diseases Related to the Dysregulation of Lipid Homeostasis.Mediators of inflammation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipids are fundamental constituents of cell membranes and play a crucial role in signaling pathways that regulate a wide array of cellular functions. Consequently, the dysregulation of lipid homeostasis is recognized as a significant contributor to metabolic diseases. Given the limitations of current strategies for regulating lipid metabolism, it is essential to explore innovative approaches to modulate lipid homeostasis to effectively address diseases associated with its dysregulation. Inflammation plays a critical role in the regulation of lipid metabolism, acting through various pathways and mechanisms that influence both lipid synthesis and degradation. The involvement of Interleukin-17 (IL-17) in inflammatory responses is particularly noteworthy, as recent studies have highlighted its impact on lipid metabolism, particularly in the context of obesity and metabolic disorders. This review critically examines the IL-17 signaling pathway, elucidates the mechanisms by which IL-17 affects lipid metabolism, and explores the therapeutic potential of targeting IL-17 in the treatment of disorders related to lipid homeostasis. This review underscores the promise of targeting IL-17 signaling pathways as a therapeutic strategy for addressing the dysregulation in lipid homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.